EXICURE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
EXICURE, INC. (XCUR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $6.30 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2025-03-18
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $1.26.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $1.54, a 73.03% increase year-over-year.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $0.89, a 55.72% decline year-over-year.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-03-31 was $2.01, a 5.63% decline year-over-year.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $6.30, a 150.00% increase from fiscal 2022.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.52, a 93.54% decline from fiscal 2021.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $39.00, a 2854.55% increase from fiscal 2020.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $1.32, a 34.33% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | $6.30 10-K · filed 2025-03-18 | $1.26 10-K · filed 2024-06-06 | |||||
| 2023-09-30 | $6.30 10-Q · filed 2024-11-14 | $1.26 10-Q · filed 2024-05-16 | |||||
| 2023-06-30 | $1.26 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | $1.26 10-Q · filed 2024-06-17 | ||||||
| 2022-12-31 | $2.52 10-K · filed 2024-06-06 | ||||||
| 2022-09-30 | $2.52 10-Q · filed 2022-11-14 | ||||||
| 2022-06-30 | $2.52 10-Q · filed 2022-08-15 | ||||||
| 2021-12-31 | $39.00 10-K · filed 2023-03-27 | $1.30 10-K · filed 2022-03-25 | |||||
| 2021-09-30 | $39.00 10-Q · filed 2022-11-14 | $1.30 10-Q · filed 2021-11-19 | |||||
| 2021-06-30 | $39.30 10-Q · filed 2022-08-15 | $1.31 10-Q · filed 2021-08-12 | |||||
| 2021-03-31 | $1.54 10-Q · filed 2022-05-16 | ||||||
| 2020-12-31 | $1.32 10-K · filed 2022-03-25 | ||||||
| 2020-09-30 | $1.33 10-Q · filed 2021-11-19 | ||||||
| 2020-06-30 | $1.29 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $0.89 10-Q · filed 2021-05-12 | ||||||
| 2019-12-31 | $2.01 10-K · filed 2021-03-11 | ||||||
| 2019-09-30 | $1.96 10-Q · filed 2020-11-12 | ||||||
| 2019-06-30 | $1.99 10-Q · filed 2020-08-12 | ||||||
| 2019-03-31 | $2.01 10-Q · filed 2020-05-14 | ||||||
| 2018-12-31 | $2.40 10-K · filed 2020-03-10 | ||||||
| 2018-09-30 | $2.40 10-Q · filed 2019-11-07 | ||||||
| 2018-06-30 | $2.27 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | $2.13 10-Q · filed 2019-05-08 | ||||||
| 2017-12-31 | $2.92 10-K/A · filed 2019-09-23 | ||||||
| 2017-09-30 | $2.92 10-Q · filed 2018-11-06 | ||||||
| 2017-06-30 | $2.92 10-Q · filed 2018-08-06 | ||||||
| 2017-03-31 | $2.92 10-Q · filed 2018-05-15 | ||||||
| 2016-12-31 | $0.90 10-K · filed 2018-03-09 | ||||||
| 2016-09-30 | $1.53 10-Q · filed 2017-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |